Descriptive Study of Acute Spontaneous Spinal Cord Infarction

Completed

• Conditions: Spinal Cord Infarction; Vascular Myelopathy; Spinal Cord Stroke

• Registration Number: NCT04372758
• Lead Sponsor: University Hospital, Montpellier

Brief Summary

Acute spontaneous Spinal Cord Infarctions (SCI) are an uncommon cause of myelopathy (5%), but their prognostic is heterogeneous and frequently severe. Positive diagnosis is difficult, one quarter of initial MRIs are normal. Differential diagnosis with other transverse myelopathy causes is a common issue. As in cerebral stroke, there are multiple causes and mechanisms in spontaneous SCI, often difficult to clearly establish. There are also clinical and radiological patterns, sometimes misleading, according to vascular territory and its expanse.

Due to its scarcity and heterogeneity, improving knowledge and medical care remains difficult. Medical care is still badly codified in medical literature. Recently, diagnostic criteria have been proposed to better identify SCI, provide earlier care and homogenize future research. External validity and reproduction of these new criteria among acute myelopathies are still to be validated.

While there is no established medical treatment in the initial care of spontaneous SCI, some case reports show successful treatment with IV thrombolysis. Given the severe prognosis, conventional treatment of strokes (thrombolysis, anticoagulant and antiplatelet), could be considered on an individual scale, in a specific protocol. A better knowledge of radio-clinical and security factors are necessary to support this approach.

In order to respond to these difficulties, a retrospective cohort will allow us to better define epidemiological, clinico-radiological and prognostic features of spontaneous SCI. It lays the foundation of a possible prospective multicentric cohort, necessary for specific therapeutic studies.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-04-29
• Study First Submitted QC: 2020-04-29
• Study First Posted: 2020-05-04
• Study Start: 2020-05-30
• Primary Completion: 2020-12-01
• Study Completion: 2021-01-01
• Status Verified: 2021-05
• Last Update Submitted: 2021-06-10
• Last Update Posted: 2021-06-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
description of a recent spontaneous SCI cohort	1 day	description of patients diagnosed with spontaneous SCI

Secondary Outcome Measures

Name	Time	Method
evaluation of JAMA 2019 diagnostic criteria in spontaneous SCI and other myelopathies	1 day	evaluation of JAMA 2019 diagnostic criteria in spontaneous SCI and other myelopathies
analysis of relevant clinical and radiological criteria for positive diagnosis and prognosis	1 day	analysis of relevant clinical and radiological criteria for positive diagnosis and prognosis
Description of clinico-radiological territories, etiology and physiopathology of spontaneous SCI, including application of fibrocartilaginous embolism criteria 2015	1 day	Description of clinico-radiological territories, etiology and physiopathology of spontaneous SCI, including application of fibrocartilaginous embolism criteria 2015
Retrospective evaluation of the potential candidates for IV thrombolysis	1 day	Retrospective evaluation of the potential candidates for IV thrombolysis
Evaluation of relevant criteria in order to create a prospective multicentric cohort of spontaneous SCI.	1 day	Evaluation of relevant criteria in order to create a prospective multicentric cohort of spontaneous SCI.

Trial Locations

Locations (1)

Uhmontpellier; 🇫🇷 Montpellier, France